Lista de obras - Pratima Chowdary - Dominio Público Uruguay

A Novel, Enriched Population Pharmacokinetic Model for Recombinant Factor VIII-Fc Fusion Protein Concentrate in Hemophilia A Patients

artículo científico publicado en 2020

A case-control study assessing bone mineral density in severe haemophilia A in the UK.

artículo científico publicado en 2014

A randomized trial of safety, pharmacokinetics and pharmacodynamics of concizumab in people with hemophilia A

scientific article published on 30 September 2018

Adenovirus-associated virus vector-mediated gene transfer in hemophilia B

artículo científico publicado en 2011

Alterations in coagulation following major liver resection

artículo científico publicado en 2016

Alternatives to warfarin--the next generation of anticoagulants.

artículo científico publicado en 2010

Anaphylactic reaction with prothrombin complex concentrate in a patient with IgA deficiency and anti-IgA antibodies

artículo científico publicado en 2010

Clinical evaluation of glycoPEGylated recombinant FVIII: Efficacy and safety in severe haemophilia A.

artículo científico publicado en 2016

Clinical utility of sample preheat treatment in a modified Nijmegen-Bethesda assay (mNBA) for inhibitor monitoring in congenital and acquired haemophilia A: A single-centre four-year experience

artículo científico publicado en 2020

Clinical utility of viscoelastic tests of coagulation in patients with liver disease.

artículo científico

Coagulation following major liver resection - a reply

artículo científico publicado en 2016

Concizumab restores thrombin generation potential in patients with haemophilia: Pharmacokinetic/pharmacodynamic modelling results of concizumab phase 1/1b data

scientific article published on 08 November 2018

Correction to: Inhibition of Tissue Factor Pathway Inhibitor (TFPI) as a Treatment for Haemophilia: Rationale with Focus on Concizumab

artículo científico publicado en 2018

Development of haemophilic arthropathy of the ankle: results of a Delphi consensus survey on potential contributory factors

artículo científico publicado en 2014

Does balanced haemostasis equate to normal coagulation in patients with acute liver failure?

artículo científico publicado en 2014

Efficacy and safety of OBI-1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A.

artículo científico publicado en 2015

Efficacy and safety of rVIII-SingleChain: results of a phase 1/3 multicenter clinical trial in severe hemophilia A.

artículo científico publicado en 2016

Efficacy of standard dose and 30 ml/kg fresh frozen plasma in correcting laboratory parameters of haemostasis in critically ill patients.

artículo científico publicado en 2004

Evaluation of a rapid von Willebrand factor activity latex immuno assay for monitoring of patients with von Willebrand disease (VWD) receiving DDAVP or VWF replacement therapy.

artículo científico publicado en 2014

Evaluation of coagulation abnormalities in acute liver failure

artículo científico publicado en 2012

Extended half-life recombinant products in haemophilia clinical practice - Expectations, opportunities and challenges

artículo científico publicado en 2019

First report on the safety and efficacy of an extended half-life glycoPEGylated recombinant FVIII for major surgery in severe haemophilia A.

artículo científico publicado en 2017

Fixed doses of N8-GP prophylaxis maintain moderate-to-mild factor VIII levels in the majority of patients with severe hemophilia A

artículo científico publicado en 2019

Guideline for the diagnosis and management of the rare coagulation disorders: a United Kingdom Haemophilia Centre Doctors' Organization guideline on behalf of the British Committee for Standards in Haematology

artículo científico publicado en 2014

Guidelines for the management of acute joint bleeds and chronic synovitis in haemophilia: A United Kingdom Haemophilia Centre Doctors' Organisation (UKHCDO) guideline

artículo científico publicado en 2017

Haemophilia clinical care and research needs: Assessing priorities

scientific article published on 13 July 2018

Hemostasis in patients with acute kidney injury secondary to acute liver failure

artículo científico publicado en 2013

History of non-fatal cardiovascular disease in a cohort of Dutch and British patients with haemophilia

artículo científico publicado en 2012

Hypercoagulability progresses to hypocoagulability during evolution of acetaminophen-induced acute liver injury in pigs.

artículo científico publicado en 2017

Impact of severe haemophilia A on patients' health status: results from the guardian(™) 1 clinical trial of turoctocog alfa (NovoEight(®) ).

artículo científico publicado en 2015

Improvement in health-related quality of life in patients with haemophilia B treated with nonacog beta pegol, a new extended half-life recombinant FIX product.

artículo científico publicado en 2016

Increased prevalence of hypertension in haemophilia patients

scientific article published on 05 September 2012

Inhibition of Tissue Factor Pathway Inhibitor (TFPI) as a Treatment for Haemophilia: Rationale with Focus on Concizumab.

artículo científico publicado en 2018

Investigating the relationship between the HJHS and HAL in routine clinical practice: A retrospective review

article

Is there an association between thrombosis and fibroids? A single centre experience and literature review

scientific article published on 01 November 2012

Laboratory coagulation tests and emicizumab treatment A United Kingdom Haemophilia Centre Doctors' Organisation guideline

artículo científico publicado en 2019

Laboratory measurement of factor replacement therapies in the treatment of congenital haemophilia: A United Kingdom Haemophilia Centre Doctors' Organisation guideline

scientific article published on 17 December 2019

Ligneous cervicitis and endometritis: A gynaecological presentation of congenital plasminogen deficiency

artículo científico publicado en 2018

Long-term safety and efficacy of factor IX gene therapy in hemophilia B.

artículo científico publicado en 2014

Long-term safety and efficacy results from the phase 3b, open-label, multicentre Continuation study of rurioctocog alfa pegol for prophylaxis in previously treated patients with severe haemophilia A

artículo científico publicado en 2020

Low-factor consumption for major surgery in haemophilia B with long-acting recombinant glycoPEGylated factor IX.

artículo científico publicado en 2016

Patients with liver cirrhosis suffer from primary haemostatic defects? Fact or fiction?

artículo científico publicado en 2011

Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A

artículo científico publicado en 2015

Perioperative replacement therapy in haemophilia B: An appeal to “B” more precise

scientific article published on 29 April 2018

Pharmacokinetic properties of IB1001, an investigational recombinant factor IX, in patients with haemophilia B: repeat pharmacokinetic evaluation and sialylation analysis.

artículo científico publicado en 2012

Pharmacokinetics, safety and efficacy of a recombinant factor IX product, trenonacog alfa in previously treated haemophilia B patients.

artículo científico publicado en 2017

Physical activity in individuals with haemophilia and experience with recombinant factor VIII Fc fusion protein and recombinant factor IX Fc fusion protein for the treatment of active patients: a literature review and case reports.

artículo científico publicado en 2016

Physiotherapy interventions for pain management in haemophilia: A systematic review

artículo científico publicado en 2020

Proceedings of the first annual congress of the European association for haemophilia and allied disorders.

artículo científico publicado en 2008

Reply to: Platelet function in patients with cirrhosis

Retinoid-induced apoptosis in B-cell chronic lymphocytic leukaemia cells is mediated through caspase-3 activation and is independent of p53, the retinoic acid receptor, and differentiation

artículo científico publicado en 2002

Retrospective Review of a Prothrombin Complex Concentrate (Beriplex P/N) for the Management of Perioperative Bleeding Unrelated to Oral Anticoagulation.

artículo científico publicado en 2018

Risk-based management of dental procedures in patients with inherited bleeding disorders: Development of a Dental Bleeding Risk Assessment and Treatment Tool (DeBRATT).

artículo científico publicado en 2017

SHP656, a polysialylated recombinant factor VIII (PSA-rFVIII): First-in-human study evaluating safety, tolerability and pharmacokinetics in patients with severe haemophilia A

artículo científico publicado en 2019

Safety and efficacy of factor XI (FXI) concentrate use in patients with FXI deficiency: a single-centre experience of 19 years.

artículo científico publicado en 2015

Safety and efficacy of turoctocog alfa (NovoEight®) during surgery in patients with haemophilia A: results from the multinational guardian™ clinical trials.

artículo científico publicado en 2014

Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial

artículo científico publicado en 2015

Targeting of Antithrombin in Hemophilia A or B with RNAi Therapy.

artículo científico publicado en 2017

The effect of neutral-cushioned running shoes on the intra-articular force in the haemophilic ankle

artículo científico publicado en 2013

The use of enhanced half-life coagulation factor concentrates in routine clinical practice: guidance from UKHCDO.

artículo científico publicado en 2016

Therapeutic and routine prophylactic properties of rFactor VIII Fc (efraloctocog alfa, Eloctate®) in hemophilia A

artículo científico publicado en 2016

Thrombin generation assay identifies individual variability in responses to low molecular weight heparin in pregnancy: implications for anticoagulant monitoring.

artículo científico publicado en 2014

Thrombin generation assays for optimizing low molecular weight heparin dosing in pregnant women at risk of thrombosis--response to Ismail et al.

artículo científico publicado en 2015

Thromboelastography in the Management of Coagulopathy Associated With Ebola Virus Disease

artículo científico publicado en 2015

Thromboelastography-guided recombinant factor VIIa administration in a patient with refractory autoimmune idiopathic thrombocytopenia

artículo científico publicado en 2008

Treatment of bleeding episodes in haemophilia A complicated by a factor VIII inhibitor in patients receiving Emicizumab. Interim guidance from UKHCDO Inhibitor Working Party and Executive Committee

scientific article published on 01 May 2018

Treatment of bleeding episodes with recombinant factor VIII Fc fusion protein in A-LONG study subjects with severe haemophilia A.

artículo científico publicado en 2017

Turoctocog alfa pegol provides effective management for major and minor surgical procedures in patients across all age groups with severe haemophilia A: Full data set from the pathfinder 3 and 5 phase III trials

scientific article published on 15 April 2020

Unfavourable cardiovascular disease risk profiles in a cohort of Dutch and British haemophilia patients

artículo científico publicado en 2012

Lista de obras de Pratima Chowdary

A Novel, Enriched Population Pharmacokinetic Model for Recombinant Factor VIII-Fc Fusion Protein Concentrate in Hemophilia A Patients

A case-control study assessing bone mineral density in severe haemophilia A in the UK.

A randomized trial of safety, pharmacokinetics and pharmacodynamics of concizumab in people with hemophilia A

Adenovirus-associated virus vector-mediated gene transfer in hemophilia B

Alterations in coagulation following major liver resection

Alternatives to warfarin--the next generation of anticoagulants.

Anaphylactic reaction with prothrombin complex concentrate in a patient with IgA deficiency and anti-IgA antibodies

Clinical evaluation of glycoPEGylated recombinant FVIII: Efficacy and safety in severe haemophilia A.

Clinical utility of sample preheat treatment in a modified Nijmegen-Bethesda assay (mNBA) for inhibitor monitoring in congenital and acquired haemophilia A: A single-centre four-year experience

Clinical utility of viscoelastic tests of coagulation in patients with liver disease.

Coagulation following major liver resection - a reply

Concizumab restores thrombin generation potential in patients with haemophilia: Pharmacokinetic/pharmacodynamic modelling results of concizumab phase 1/1b data

Correction to: Inhibition of Tissue Factor Pathway Inhibitor (TFPI) as a Treatment for Haemophilia: Rationale with Focus on Concizumab

Development of haemophilic arthropathy of the ankle: results of a Delphi consensus survey on potential contributory factors

Does balanced haemostasis equate to normal coagulation in patients with acute liver failure?

Efficacy and safety of OBI-1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A.

Efficacy and safety of rVIII-SingleChain: results of a phase 1/3 multicenter clinical trial in severe hemophilia A.

Efficacy of standard dose and 30 ml/kg fresh frozen plasma in correcting laboratory parameters of haemostasis in critically ill patients.

Evaluation of a rapid von Willebrand factor activity latex immuno assay for monitoring of patients with von Willebrand disease (VWD) receiving DDAVP or VWF replacement therapy.

Evaluation of coagulation abnormalities in acute liver failure

Extended half-life recombinant products in haemophilia clinical practice - Expectations, opportunities and challenges

First report on the safety and efficacy of an extended half-life glycoPEGylated recombinant FVIII for major surgery in severe haemophilia A.

Fixed doses of N8-GP prophylaxis maintain moderate-to-mild factor VIII levels in the majority of patients with severe hemophilia A

Guideline for the diagnosis and management of the rare coagulation disorders: a United Kingdom Haemophilia Centre Doctors' Organization guideline on behalf of the British Committee for Standards in Haematology

Guidelines for the management of acute joint bleeds and chronic synovitis in haemophilia: A United Kingdom Haemophilia Centre Doctors' Organisation (UKHCDO) guideline

Haemophilia clinical care and research needs: Assessing priorities

Hemostasis in patients with acute kidney injury secondary to acute liver failure

History of non-fatal cardiovascular disease in a cohort of Dutch and British patients with haemophilia

Hypercoagulability progresses to hypocoagulability during evolution of acetaminophen-induced acute liver injury in pigs.

Impact of severe haemophilia A on patients' health status: results from the guardian(™) 1 clinical trial of turoctocog alfa (NovoEight(®) ).

Improvement in health-related quality of life in patients with haemophilia B treated with nonacog beta pegol, a new extended half-life recombinant FIX product.

Increased prevalence of hypertension in haemophilia patients

Inhibition of Tissue Factor Pathway Inhibitor (TFPI) as a Treatment for Haemophilia: Rationale with Focus on Concizumab.

Investigating the relationship between the HJHS and HAL in routine clinical practice: A retrospective review

Is there an association between thrombosis and fibroids? A single centre experience and literature review

Laboratory coagulation tests and emicizumab treatment A United Kingdom Haemophilia Centre Doctors' Organisation guideline

Laboratory measurement of factor replacement therapies in the treatment of congenital haemophilia: A United Kingdom Haemophilia Centre Doctors' Organisation guideline

Ligneous cervicitis and endometritis: A gynaecological presentation of congenital plasminogen deficiency

Long-term safety and efficacy of factor IX gene therapy in hemophilia B.

Long-term safety and efficacy results from the phase 3b, open-label, multicentre Continuation study of rurioctocog alfa pegol for prophylaxis in previously treated patients with severe haemophilia A

Low-factor consumption for major surgery in haemophilia B with long-acting recombinant glycoPEGylated factor IX.

Patients with liver cirrhosis suffer from primary haemostatic defects? Fact or fiction?

Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A

Perioperative replacement therapy in haemophilia B: An appeal to “B” more precise

Pharmacokinetic properties of IB1001, an investigational recombinant factor IX, in patients with haemophilia B: repeat pharmacokinetic evaluation and sialylation analysis.

Pharmacokinetics, safety and efficacy of a recombinant factor IX product, trenonacog alfa in previously treated haemophilia B patients.

Physical activity in individuals with haemophilia and experience with recombinant factor VIII Fc fusion protein and recombinant factor IX Fc fusion protein for the treatment of active patients: a literature review and case reports.

Physiotherapy interventions for pain management in haemophilia: A systematic review

Proceedings of the first annual congress of the European association for haemophilia and allied disorders.

Reply to: Platelet function in patients with cirrhosis

Retinoid-induced apoptosis in B-cell chronic lymphocytic leukaemia cells is mediated through caspase-3 activation and is independent of p53, the retinoic acid receptor, and differentiation

Retrospective Review of a Prothrombin Complex Concentrate (Beriplex P/N) for the Management of Perioperative Bleeding Unrelated to Oral Anticoagulation.

Risk-based management of dental procedures in patients with inherited bleeding disorders: Development of a Dental Bleeding Risk Assessment and Treatment Tool (DeBRATT).

SHP656, a polysialylated recombinant factor VIII (PSA-rFVIII): First-in-human study evaluating safety, tolerability and pharmacokinetics in patients with severe haemophilia A

Safety and efficacy of factor XI (FXI) concentrate use in patients with FXI deficiency: a single-centre experience of 19 years.

Safety and efficacy of turoctocog alfa (NovoEight®) during surgery in patients with haemophilia A: results from the multinational guardian™ clinical trials.

Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial

Targeting of Antithrombin in Hemophilia A or B with RNAi Therapy.

The effect of neutral-cushioned running shoes on the intra-articular force in the haemophilic ankle

The use of enhanced half-life coagulation factor concentrates in routine clinical practice: guidance from UKHCDO.

Therapeutic and routine prophylactic properties of rFactor VIII Fc (efraloctocog alfa, Eloctate®) in hemophilia A

Thrombin generation assay identifies individual variability in responses to low molecular weight heparin in pregnancy: implications for anticoagulant monitoring.

Thrombin generation assays for optimizing low molecular weight heparin dosing in pregnant women at risk of thrombosis--response to Ismail et al.

Thromboelastography in the Management of Coagulopathy Associated With Ebola Virus Disease

Thromboelastography-guided recombinant factor VIIa administration in a patient with refractory autoimmune idiopathic thrombocytopenia

Treatment of bleeding episodes in haemophilia A complicated by a factor VIII inhibitor in patients receiving Emicizumab. Interim guidance from UKHCDO Inhibitor Working Party and Executive Committee

Treatment of bleeding episodes with recombinant factor VIII Fc fusion protein in A-LONG study subjects with severe haemophilia A.

Turoctocog alfa pegol provides effective management for major and minor surgical procedures in patients across all age groups with severe haemophilia A: Full data set from the pathfinder 3 and 5 phase III trials

Unfavourable cardiovascular disease risk profiles in a cohort of Dutch and British haemophilia patients